Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease
- PMID: 16815259
- DOI: 10.1016/j.ajo.2006.02.049
Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease
Abstract
Purpose: To compare the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.
Design: Retrospective comparative interventional case series.
Settings: Nine international uveitis specialty clinics.
Study population: Forty-eight patients presenting over a three-year period to a study center with acute Vogt-Koyanagi-Harada disease.
Intervention: Initial treatment with corticosteroid either orally (Oral only group) or intravenously followed by an oral taper (IV+Oral group).
Main outcome measures: Change in visual acuity with treatment; development of ocular complications, including visually significant cataract, choroidal neovascularization, subretinal fibrosis, fundus pigment migration, nummular hypopigmented lesions, and diffuse fundus depigmentation; use of immunosuppressive therapy.
Results: The Oral only group comprised 15 patients (31%) and the IV+Oral group 33 patients (69%). Median follow-up was 15 months. There was no difference in duration of follow-up between groups (P = .234). There was no difference in the change in visual acuity between groups, adjusting for initial visual acuity (P = .402). There were no differences in the rates of development of visually significant cataract, fundus pigmentary changes, or in the rate of use of subsequent immunosuppressive therapy between treatment groups. No patients developed choroidal neovascularization or subretinal fibrosis over the study period.
Conclusions: Route of administration of corticosteroid had no detectable effect on change in visual acuity nor on the development of visually significant complications over the study period. Prospective trials are necessary to address speed of resolution and definitively answer outcome questions.
Similar articles
-
Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease.Eye (Lond). 2009 Mar;23(3):543-8. doi: 10.1038/eye.2008.89. Epub 2008 Mar 28. Eye (Lond). 2009. PMID: 18369377
-
The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1203-1211. doi: 10.1007/s00417-017-3654-5. Epub 2017 Apr 5. Graefes Arch Clin Exp Ophthalmol. 2017. PMID: 28382438
-
Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.Acta Ophthalmol. 2017 Feb;95(1):85-90. doi: 10.1111/aos.13189. Epub 2016 Aug 18. Acta Ophthalmol. 2017. PMID: 27535102
-
[Vogt-Koyanagi-Harada disease complicated by subretinal neovessels].J Fr Ophtalmol. 1995;18(4):305-11. J Fr Ophtalmol. 1995. PMID: 7769166 Review. French.
-
Vogt-koyanagi-harada syndrome.Curr Eye Res. 2008 Jul;33(7):517-23. doi: 10.1080/02713680802233968. Curr Eye Res. 2008. PMID: 18600484 Review.
Cited by
-
Intravitreal triamcinolone acetonide for rebound phenomenon after high-dose intravenous steroid treatment in Vogt-Koyanagi-Harada disease.Clin Ophthalmol. 2011;5:1589-91. doi: 10.2147/OPTH.S25477. Epub 2011 Nov 4. Clin Ophthalmol. 2011. PMID: 22125406 Free PMC article.
-
Rituximab in refractory Vogt-Koyanagi-Harada disease.J Ophthalmic Inflamm Infect. 2011 Dec;1(4):177-80. doi: 10.1007/s12348-011-0027-9. Epub 2011 Jul 9. J Ophthalmic Inflamm Infect. 2011. PMID: 21744181 Free PMC article.
-
Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies.Am J Ophthalmol. 2016 Aug;168:279-286. doi: 10.1016/j.ajo.2016.06.004. Epub 2016 Jun 10. Am J Ophthalmol. 2016. PMID: 27296490 Free PMC article. Clinical Trial.
-
A Case of Pneumatic Displacement with Gas Tamponade Performed for Macular Subretinal Hemorrhage Complicating Vogt-Koyanagi-Harada Disease.Case Rep Ophthalmol. 2020 Mar 19;11(1):143-150. doi: 10.1159/000506436. eCollection 2020 Jan-Apr. Case Rep Ophthalmol. 2020. PMID: 32308616 Free PMC article.
-
Clinical spectrum and management options in Vogt-Koyanagi-Harada disease.Clin Ophthalmol. 2017 Aug 7;11:1399-1406. doi: 10.2147/OPTH.S134977. eCollection 2017. Clin Ophthalmol. 2017. PMID: 28848322 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical